Related Experiment Video
Updated: Jan 25, 2026

Collecting Hair Samples for Hair Cortisol Analysis in African Americans
Published on: June 10, 2018
Differences in plasma levels of long chain and very long chain ceramides between African Americans and whites: An
Joy N Jones Buie1,2, Samar M Hammad3, Paul J Nietert4
1WISSDOM Center, Medical University of South Carolina, Charleston, SC, United States of America.
Insights
African Americans exhibit distinct plasma ceramide levels, particularly with metabolic disorders. These sphingolipid differences may explain disparities in cardiovascular disease (CVD) risk and inform future therapeutic strategies.
Area of Science:
- Biochemistry
- Cardiovascular Medicine
- Health Disparities
Background:
- Cardiovascular disease (CVD) reductions are not uniform across populations, with African Americans facing a disproportionately higher burden of CVD risk factors like metabolic disorders and obesity.
- Sphingolipids, including ceramide, sphingosine, and sphingosine 1-phosphate (S1P), are implicated in the pathogenesis of CVD, metabolic disorders (MetD), and obesity.
- It remains unclear whether African Americans possess distinct sphingolipid expression profiles that contribute to their elevated CVD risk.
Purpose of the Study:
- To investigate potential racial disparities in plasma sphingolipid concentrations between White and African American individuals.
- To determine if metabolic disorders influence these sphingolipid levels differently across racial groups.
- To explore the association between specific sphingolipids and metabolic disease markers in African Americans.
Main Methods:
- Cross-sectional analysis of plasma concentrations of ceramides, sphingosine, and S1P.
- Participants were stratified by race (White, African American) and metabolic status (presence or absence of MetD).
- High-performance liquid chromatography/tandem mass spectrometry (HPLC/MS-MS) was used for quantification, with data analyzed via Two-Way ANOVA and Tukey's post hoc test.
Main Results:
- Distinct plasma ceramide profiles were observed in African Americans, particularly those with MetD.
- Specific ceramides (C16, C20, C24:0, C24:1) showed differential concentrations between racial groups and metabolic statuses.
- Plasma sphingosine-1-phosphate (Sph-1P) ceramide was significantly higher in African Americans compared to Whites, and ceramide C20 negatively correlated with hemoglobin A1c (HbA1c).
Conclusions:
- Plasma ceramide concentration patterns are notably distinct in African Americans with metabolic disorders.
- These findings suggest potential racial disparities in sphingolipid metabolism that warrant further investigation.
- Larger studies are needed to confirm these results and explore the therapeutic implications for CVD-related health outcomes.
Background:
Population-wide reductions in cardiovascular disease (CVD) have not been equally shared in the African American community due to a higher burden of CVD risk factors such as metabolic disorders and obesity. Differential concentrations of sphingolipids such as ceramide, sphingosine, and sphingosine 1-phosphate (S1P) has been associated with the development of CVD, metabolic disorders (MetD), and obesity. Whether African Americans have disparate expression levels of sphingolipids that explain higher burdens of CVD remains unknown.
Methods:
A cross sectional analysis of plasma concentrations of ceramides, sphingosine, and S1P were measured from 8 whites and 7 African Americans without metabolic disorders and 7 whites and 8 African Americans with metabolic disorders using high performance liquid chromatography/tandem mass spectrometry methodology (HPLC/MS-MS). Subjects were stratified by both race and metabolic status. Subjects with one or more of the following physician confirmed diagnosis: diabetes, hypertension, hypercholesterolemia, or dyslipidemia were classified as having metabolic disease (MetD). Data was analyzed using a Two-Way ANOVA and Tukey's post hoc test.
Results:
Total ceramide levels were increased in African Americans compared to African Americans with MetD. Ceramide C16 levels were higher in whites with MetD compared to African Americans with MetD (p<0.05). Ceramide C20 levels were higher in whites with MetD compared to whites. Ceramide C20 levels were higher in African Americans compared to African Americans with MetD. Furthermore, whites with MetD had higher levels of C20 compared to African Americans with MetD (p<0.0001). Ceramide C24:0 and C24:1 in African Americans was higher compared to African Americans with MetD (p<0.05). The plasma concentration of Sph-1P ceramide was higher in African Americans vs whites (p = 0.01). Lastly, ceramide C20 negatively correlated with hemoglobin A1c (HbA1c) levels in our study cohort.
Conclusions:
Plasma ceramide concentration patterns are distinct in African Americans with MetD. Further research with larger samples sizes are needed to confirm these findings and to understand whether racial disparities in sphingolipid concentrations have potential therapeutic implications for CVD-related health outcomes.
Related Concept Videos
Electron Transport Chains
The ETC is comprised of...
Radical Chain-Growth Polymerization: Chain Branching
The Chain Rule
The Chain Rule: Problem Solving
The Electron Transport Chain
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...

